Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2003
Business Overview: DaVita operates dialysis centers and laboratories, providing end-stage renal disease (ESRD) services. The company generates revenue primarily from Medicare, Medicaid, and private payors. As of July 31, 2003, approximately 66.5 million shares of common stock were outstanding.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2003 | Six Months Ended June 30, 2003 |
|---|---|---|
| Net Operating Revenues | $489.9 million | $949.7 million |
| Operating Income | $82.8 million | $162.1 million |
| Net Earnings | $38.5 million | $74.9 million |
| Diluted Earnings Per Share | $0.55 | $1.07 |
| Cash and Cash Equivalents | $315.6 million (Balance Sheet) | N/A |
| Net Cash Provided by Operating Activities | N/A | $159.4 million |
| Total Debt (Current + Long-term) | $1,457.0 million | N/A |
| Operating Margin | 16.9% | 17.1% |
Note: All dollar amounts in millions unless otherwise specified. Debt figures represent total long-term debt obligations including current portion.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 11% ($47 million) in Q2 2003 compared to Q2 2002. This was driven by a 6% increase in dialysis treatments and a 4% increase in average reimbursement rates. Approximately $5 million of the increase was attributable to the recognition of Medicare laboratory revenue, which was withheld in the prior year.
- Profitability: Net earnings surged to $38.5 million in Q2 2003 from $8.4 million in Q2 2002. This significant improvement is largely due to the absence of a $48.9 million refinancing charge recorded in Q2 2002 (related to debt extinguishment) and improved operational margins.
- Expense Trends: Dialysis center and lab expenses rose to 69% of revenue in Q2 2003 from 68% in Q2 2002, driven by higher labor, benefits, insurance, and pharmaceutical costs. General and administrative expenses remained stable at 9% of revenue.
- Liquidity: Cash and cash equivalents increased significantly from $96.5 million at year-end 2002 to $315.6 million at June 30, 2003, bolstered by strong operating cash flows and financing activities.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2003 Projection: Operating income for the full year 2003 is projected to be between $315 million and $330 million.
- 2004 Projection: Operating income for 2004 is expected to be relatively flat compared to 2003.
- Growth Drivers: Management expects non-acquired treatment growth to remain in the 3.0% to 5.0% range for 2003. Revenue per treatment increased to $301.52 in Q2 2003, up from $290.52 in Q2 2002, due to improved pricing, payor mix, and billing improvements.
Recent Capital Actions (Post-Period)
- Debt Refinancing: On July 15, 2003, the company refinanced its Term Loan B for $1.04 billion, lowering the effective interest rate to 3.6% (LIBOR + 2.5%).
- Note Redemption: The company redeemed all $125 million of its 5 5/8% Convertible Subordinated Notes due 2006 (mostly converted to stock). Additionally, on July 16, 2003, it announced a call for redemption of $200 million of its 7% Convertible Subordinated Notes due 2009.
Risks and Contingencies
- Regulatory Investigations: The company is under review by the U.S. Attorney's Office and the Office of Inspector General (OIG) regarding historical billing practices and financial relationships with physicians. The outcome could result in substantial penalties.
- Laboratory Disputes: A Florida laboratory subsidiary faces ongoing Medicare carrier reviews regarding claims from 1995–2001. While $68.8 million was collected in late 2002, approximately $31.5 million in claims remain in dispute across various review periods.
- Reimbursement Risk: Approximately 45% of revenue comes from private payors and 49% from Medicare. Declines in reimbursement rates or changes in clinical practices (e.g., EPO administration) could materially reduce earnings.
- IT Implementation: The rollout of new information technology systems may disrupt billing and collection activities over the next nine months.
Investor Verification Checklist
- Debt Structure: Verify the impact of the July 2003 refinancing on future interest expense and the terms of the new Term Loan B.
- Regulatory Exposure: Monitor the status of the U.S. Attorney's Office/OIG inquiry and the Florida laboratory Medicare dispute for potential financial penalties or revenue adjustments.
- Reimbursement Rates: Track changes in Medicare composite rates and private payor contracts, particularly regarding EPO and other pharmaceutical reimbursements.
- Operational Growth: Confirm if the projected 3.0%–5.0% non-acquired treatment growth rate is being met in subsequent quarters.
- IT Rollout: Assess the impact of new billing systems on days sales outstanding (DSO) and cash collection efficiency.